原发性肝癌的抗血管生成靶向治疗现状与挑战

Present Status and Challenges of Targeted Drugs on Antiangiogenesis in Primary Hepatic Carcinoma

血管生成在原发性肝癌的肿瘤增殖、侵袭和转移中起着重要作用。在过去10年里,针对抗肿瘤血管生成靶向药物在原发性肝癌的临床前和临床试验中获得了显著疗效。血管生成是受多因子调节的复杂过程,而VEGF/VEGFR、PDGF/PDGFR、FGF/FGFR、Ang/tie-2可直接影响血管内皮细胞的生长,刺激新生血管的形成。全文就原发性肝癌血管生成机制和相关分子靶向药物的研究进展进行综述。

Angiogenesis plays an important role in tumor proliferation,invasion and metastasis. Preclinical and clinical trials of targeted drugs on anti-tumor angiogenesis have been conducted and shown promissing results since last decade. Angiogenesis is a complex progress regulated by multiple factors,VEGF/VEGFR,PDGF/PDGFR,FGF/FGFR and Ang/tie-2 affect the growth of endothelial cells directly and promote the formation of new blood vessels.This article attempts to review the mechanism of angiogenesis and the research progress of molecular targeted drugs on anti-angiogenesis in primary hepatic carcinoma.